[go: up one dir, main page]

MX9700245A - Nuevo compuesto quimico, su preparacion y su empleo como medicamento. - Google Patents

Nuevo compuesto quimico, su preparacion y su empleo como medicamento.

Info

Publication number
MX9700245A
MX9700245A MX9700245A MX9700245A MX9700245A MX 9700245 A MX9700245 A MX 9700245A MX 9700245 A MX9700245 A MX 9700245A MX 9700245 A MX9700245 A MX 9700245A MX 9700245 A MX9700245 A MX 9700245A
Authority
MX
Mexico
Prior art keywords
medicine
preparation
chemical compound
new chemical
formula
Prior art date
Application number
MX9700245A
Other languages
English (en)
Inventor
Ralf Anderskewitz
Kurt Schromm
Ernst-Otto Renth
Franz Birke
Armin Fugner
Hubert Heuer
Christopher Meade
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of MX9700245A publication Critical patent/MX9700245A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

El nuevo compuesto de la formula (Ver Formula), se puede prepara segun métodos convencionales y utilizar terapéuticamente como antagonistas del receptor del LTB.
MX9700245A 1994-07-13 1995-06-03 Nuevo compuesto quimico, su preparacion y su empleo como medicamento. MX9700245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4424714A DE4424714A1 (de) 1994-07-13 1994-07-13 Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff
PCT/EP1995/002113 WO1996002496A1 (de) 1994-07-13 1995-06-03 Neue chemische verbindung, ihre herstellung und ihre verwendung als arzneistoff

Publications (1)

Publication Number Publication Date
MX9700245A true MX9700245A (es) 1997-05-31

Family

ID=6523048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700245A MX9700245A (es) 1994-07-13 1995-06-03 Nuevo compuesto quimico, su preparacion y su empleo como medicamento.

Country Status (25)

Country Link
US (1) US5686496A (es)
EP (1) EP0770058A1 (es)
JP (1) JPH10502646A (es)
KR (1) KR970704674A (es)
CN (1) CN1152303A (es)
AU (1) AU2736895A (es)
BG (1) BG101104A (es)
BR (1) BR9508395A (es)
CA (1) CA2194886A1 (es)
CO (1) CO4410185A1 (es)
CZ (1) CZ8297A3 (es)
DE (1) DE4424714A1 (es)
EE (1) EE9700065A (es)
FI (1) FI970095A0 (es)
HR (1) HRP950363A2 (es)
HU (1) HUT76827A (es)
IL (1) IL114572A0 (es)
MX (1) MX9700245A (es)
NO (1) NO970123D0 (es)
PE (1) PE35196A1 (es)
PL (1) PL318114A1 (es)
SK (1) SK1897A3 (es)
WO (1) WO1996002496A1 (es)
YU (1) YU45395A (es)
ZA (1) ZA955781B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191169B1 (en) 1992-08-28 2001-02-20 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
US6486181B1 (en) 1992-08-28 2002-11-26 City Of Hope Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states
EP0743064A1 (en) * 1995-05-17 1996-11-20 Eli Lilly And Company Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease
DE19546452A1 (de) * 1995-12-13 1997-06-19 Boehringer Ingelheim Kg Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel
DE19636689A1 (de) * 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate
DE19718334A1 (de) * 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Neue Benzylaminderivate und Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ID24720A (id) 1997-12-12 2000-08-03 Novartis Ag Senyawa amidino tersubstitusi dalam perawatan penyakit gangguan paru-paru kronis
DE19834713A1 (de) * 1998-07-31 2000-02-03 Boehringer Ingelheim Pharma Neue Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6528491B2 (en) * 2000-10-24 2003-03-04 Boehringer Ingelheim Pharma Kg Pyranoside derivatives
MXPA03006328A (es) * 2001-01-16 2004-04-05 Boehringer Ingelheim Pharma Uso de antagonista de ltb4 para tratamiento y/o prevencion de enfermedades causadas por aumento de expresion de genes de mucina.
US20040006092A1 (en) * 2001-08-31 2004-01-08 Neurochem, Inc. Amidine derivatives for treating amyloidosis
EP1623231A2 (en) * 2003-05-06 2006-02-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
KR100682199B1 (ko) * 2004-07-05 2007-02-12 동화약품공업주식회사 알러지성 염증 질환의 예방 및 치료용 조성물
DE602005023797D1 (de) * 2004-07-14 2010-11-04 Inflammation Res Ct Co Ltd Verfahren zur Hemmung von Tumormetastasierung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518818A3 (en) * 1991-06-11 1993-04-28 Ciba-Geigy Ag Arylethers, their manufacture and use as medicament
PL173781B1 (pl) * 1992-02-05 1998-04-30 Boehringer Ingelheim Kg Sposób wytwarzania nowych pochodnych amidyny

Also Published As

Publication number Publication date
FI970095A7 (fi) 1997-01-10
CZ8297A3 (en) 1997-09-17
JPH10502646A (ja) 1998-03-10
HUT76827A (en) 1997-11-28
CO4410185A1 (es) 1997-01-09
ZA955781B (en) 1996-02-22
PE35196A1 (es) 1996-09-05
YU45395A (sh) 1997-12-05
IL114572A0 (en) 1995-11-27
EE9700065A (et) 1997-08-15
EP0770058A1 (de) 1997-05-02
CN1152303A (zh) 1997-06-18
CA2194886A1 (en) 1996-02-01
NO970123L (no) 1997-01-10
BG101104A (en) 1998-04-30
PL318114A1 (en) 1997-05-12
HU9700060D0 (en) 1997-02-28
FI970095L (fi) 1997-01-10
DE4424714A1 (de) 1996-01-18
HRP950363A2 (en) 1997-08-31
SK1897A3 (en) 1997-08-06
US5686496A (en) 1997-11-11
BR9508395A (pt) 1997-12-23
FI970095A0 (fi) 1997-01-10
NO970123D0 (no) 1997-01-10
KR970704674A (ko) 1997-09-06
AU2736895A (en) 1996-02-16
WO1996002496A1 (de) 1996-02-01

Similar Documents

Publication Publication Date Title
MX9700245A (es) Nuevo compuesto quimico, su preparacion y su empleo como medicamento.
GEP20074144B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
MY137535A (en) New pyrrolidinium derivatives
PE20211700A1 (es) Compuesto heterociclico y su uso
HN1998000155A (es) Medicamentos
AU1192302A (en) Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
SE8804629D0 (sv) New therapeutically active compounds
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
AP1789A (en) Tropane derivatives useful in therapy.
ES2168737T3 (es) Inhibidores de la oxido nitrico sintasa.
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
ES2176212T3 (es) Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.
DE60023141T2 (de) Selektive npy (y5) antagonisten
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
YU57600A (sh) Derivarti biciklične hidroksaminske kiseline
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
BR0110492A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto
UY27127A1 (es) Derivados de la urea como antagonistas de integrin alfa-4
SE0100569D0 (sv) New compounds
PE20070093A1 (es) Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
MX9700273A (es) Benzamidinas sustituidas, su preparacion y empleo como sustancias medicamentosas.
SE0102055D0 (sv) New Compounds
IT1255802B (it) Derivati imidazolici ad attivita' a ii antagonista
BR0208205A (pt) Derivados de benzimidazol moduladores de receptores de quimocinas